Nanjing King-Friend Biochemical Pharmaceutical Co.,Ltd. (SHA:603707)

Market Cap	13.78B -21.5%
Revenue (ttm)	4.03B +6.0%
Net Income	585.83M -20.2%
EPS	0.36 -18.4%
Shares Out	1.62B
PE Ratio	23.83
Forward PE	13.33
Dividend	0.10 (1.17%)
Ex-Dividend Date	Jun 5, 2025

Volume	2,112,128
Average Volume	9,799,091
Open	8.53
Previous Close	8.53
Day's Range	8.36 - 8.56
52-Week Range	8.37 - 12.27
Beta	0.62
RSI	25.25
Earnings Date	Apr 30, 2026

About SHA:603707

Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd manufactures and sells heparin sodium and low molecular weight heparin products for pharmaceutical companies in the People's Republic of China. It offers enoxaparin sodium, dalteparin sodium, and naqu heparin calcium injections. The company also exports its products primarily to the European and American countries. The company was founded in 2000 and is based in Nanjing, the People's Republic of China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 1,360
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603707

Financial Performance

In 2025, SHA:603707's revenue was 3.99 billion, an increase of 1.71% compared to the previous year's 3.92 billion. Earnings were 581.54 million, a decrease of -29.61%.